Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
Hear patients supported by You First discuss the impact the programme has had on their life.
You First: Jane’s patient experience
Hear You First patient Jane discussing how the You First programme has supported her to manage her plaque psoriasis.
You First: Catherine’s patient experience
You First patient Catherine and You First nurse Sue, discuss the support that the dedicated You First nurse can provide to patients with plaque psoriasis.
CRP, c-reactive protein; DMARD, disease modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate.